Ann: ResApp to Present at Wilsons Healthcare IT Conference, page-30

Thanks appreciate your comments. Yes,, the market cap might be an issue though it does seem to reflect confidence in RAP achieving its goals, including monetisation. Why do you think realistic monetisation is unacheivable though? Why would MGH, those other hopsitals, and WHO/ UNESCO jump aboard so willingly if this wasnt a very viable proposition. Also it might not get to monetisation as, if prior results are any indication of the success of the coming US trials, this technology is far far too valuable and impartant to not to be put to use and could be the subject of a T/O The principle risk seems to me to be in the trials.

Regards